Systems and methods for real-time monitoring of physiological biomarkers through nerve signals and uses thereof

Patent metadata

Field	Value
Publication number	US-11872371-B2
Application number	US-201816605818-A
Country	US
Kind code	B2
Filing date	Apr 19, 2018
Priority date	Apr 20, 2017
Publication date	Jan 16, 2024
Grant date	Jan 16, 2024

Abstract

The present disclosure relates to systems, methods and devices to monitor, diagnose and/or treat diseases or disorders comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, the calibration phase correlating a plurality of nerve activity measurements from a chronically implanted electrode in a subject with a plurality of concurrent measurements of levels of cytokines and/or glucose in the blood to obtain a functional relationship between blood cytokine and/or glucose levels and vagus nerve activity, and the diagnostic, treatment or monitoring phase analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship to initiate a treatment method.

First claim

What is claimed is:

1. A method for diagnosing or treating or monitoring symptoms in a subject with diabetes based on the subject's nerve activity, wherein the nerve activity consists of vagus nerve activity, comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, wherein the calibration phase precedes the real-time diagnostic, treatment or monitoring phase, and wherein
the calibration phase comprises correlating a plurality of nerve activity measurements from a chronically implanted recording electrode in the subject, wherein the nerve activity measurements consists of vagus nerve activity measurements, with a plurality of concurrent measurements of glucose levels in the blood of the subject to obtain a functional relationship between blood glucose levels and vagus nerve activity recorded from the chronically implanted recording electrode in the subject, wherein the blood glucose measurements during the calibration phase consist of one or more of blood glucose levels that fluctuate naturally in the subject and blood glucose levels that occur in response to administration of one or more of insulin, glucose and glucagon to the subject; and
the real-time diagnostic, treatment or monitoring phase comprises analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship between blood glucose levels and vagus nerve activity to initiate a treatment method, wherein the treatment method consists of one or more of administering insulin, glucose or glucagon to the subject, and applying acoustic energy stimulus to the subject.

2. The method of claim 1 , wherein the subject has type 1 diabetes or type 2 diabetes.

3. The method of claim 1 , wherein the calibration phase comprises the following steps in sequential order:
i) signal conditioning and decomposition of a raw vagus nerve recording to obtain a conditioned and decomposed signal,
ii) feature detection of the signal obtained in i) to obtain a signal with feature detection,
iii) dimensionality reduction and unsupervised classification of the signal obtained in ii) to obtain a signal with dimensionality reduction and unsupervised classification,
iv) neural response extraction of the signal obtained in iii) to obtain a signal with event rates,
v) low-pass filtering the signal with event rates to obtain a smoothed event rate signal, and
vi) lagged linear regression of the smoothed event rate signals to obtain a mapping between the neural event rate signals and the blood glucose levels.

4. The method of claim 1 , which further comprises a recalibration phase after the treatment phase and before a subsequent treatment phase.

5. The method of claim 1 , wherein the chronically implanted recording electrode is chronically implanted on the subject's cervical vagus nerve or hepatic vagus nerve.

6. The method of claim 1 , wherein the subject is a human.

7. A method for diagnosing or treating or monitoring symptoms in a subject with a cytokine-mediated disease or disorder based on the subject's vagus nerve activity, comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, wherein the calibration phase precedes the real-time diagnostic, treatment or monitoring phase, and wherein
the calibration phase comprises correlating a plurality of vagus nerve activity measurements from a chronically implanted recording electrode in the subject with a plurality of concurrent measurements of levels of one or more cytokines in the blood of the subject to obtain a functional relationship between blood cytokine levels and vagus nerve activity recorded from the chronically implanted recording electrode in the subject, wherein the blood cytokine measurements during the calibration phase consist of one or more of blood cytokine levels that fluctuate naturally in the subject and blood cytokine levels that occur in response to administration of one or more of a cytokine and a cytokine antagonist or inhibitor to the subject; and
the real-time diagnostic, treatment or monitoring phase comprises analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship between blood cytokine levels and vagus nerve activity to initiate a treatment method, wherein the treatment method consists of one or more of administering a cytokine antagonist or inhibitor to the subject and applying acoustic energy stimulus to the subject;
wherein the disease or disorder is one or more of type 1 diabetes, type 2 diabetes, obesity, trauma, hemorrhagic shock, ischemia-reperfusion injury, colitis, sepsis, pancreatitis, myasthenia gravis, multiple sclerosis, systemic lupus erythematosus, autoimmune thyroiditis (Hashimoto's thyroiditis), Graves' disease, autoimmune uveoretinitis, polymyositis, fever, and swelling.

8. The method of claim 7 , wherein the one or more cytokine is one or more of a chemokine, a colony stimulating factor, high-mobility group protein B1 (HMGB1), an interferon (IFN), an interleukin (e.g., any of IL-1 through IL-36), a lymphokine, macrophage migration inhibitory factor (MIF), a monokine, a transforming growth factor beta (e.g., TGF-β1, TGF-β2 and TGF-β3), and a tumor necrosis factor (e.g., TNFα or TNFβ).

9. The method of claim 7 , wherein the calibration phase comprises the following steps in sequential order:
i) signal conditioning and decomposition of a raw vagus nerve recording to obtain a conditioned and decomposed signal,
ii) feature detection of the signal obtained in i) to obtain a signal with feature detection,
iii) dimensionality reduction and unsupervised classification of the signal obtained in ii) to obtain a signal with dimensionality reduction and unsupervised classification,
iv) neural response extraction of the signal obtained in iii) to obtain a signal with event rates, and
v) passing the signal with event rates through a decoder to obtain a mapping between nerve signals and blood cytokine levels.

10. The method of claim 7 , which further comprises a recalibration phase after the treatment phase and before a subsequent treatment phase.

11. The method of claim 7 , wherein the chronically implanted recording electrode is chronically implanted on the subject's cervical vagus nerve or hepatic vagus nerve.

12. The method of claim 7 , wherein the subject is a human.

13. An implantable system for monitoring, diagnosing and/or treating a disease or disorder in a subject, wherein the system comprises
one or more pairs of implantable electrodes for recording nerve activity from the subject, wherein the nerve activity consists of vagus nerve activity,
an implantable interface to capture the nerve activity,
an implantable digitizer to digitize the nerve activity,
an implantable processor for processing the digitized nerve activity,
an implantable rechargeable or replaceable battery; and
a wireless external device interface for inputting biological signals to the processor and for outputting signals from the processor;
wherein the system is programmed to correlate a plurality of vagus nerve activity measurements from the subject with a plurality of concurrent measurements of levels of one or more cytokines and/or glucose in the blood of the subject to obtain a functional relationship between blood cytokine levels and/or blood glucose levels and vagus nerve activity recorded from the subject; and to provide real-time diagnostic, treatment or monitoring recommendations by-analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship, and
wherein the treatment consists of one or more of administering

Assignees

• Feinstein Institutes For Medical Research

Inventors

• Zanos Theodoros
• Levy Todd
• Battinelli Emily
• Tracey Kevin J
• Bouton Chad E
• Chavan Sangeeta
• Silverman Harold

Classifications

• A61M5/1723 Primary

  using feedback of body parameters, e.g. blood-sugar, pressure (measurement of body parameters A61B5/00) · CPC title

• A61B5/14532

  for measuring glucose, e.g. by tissue impedance measurement · CPC title

• A61B5/14546

  for measuring analytes not otherwise provided for, e.g. ions, cytochromes · CPC title

• A61B5/388

  Nerve conduction study, e.g. detecting action potential of peripheral nerves · CPC title

• A61B5/7225

  Details of analogue processing, e.g. isolation amplifier, gain or sensitivity adjustment, filtering, baseline or drift compensation (input circuits for detecting, measuring, or recording bioelectric or biomagnetic signals A61B5/30; specific diagnostic methods using bioelectric or biomagnetic signals A61B5/316) · CPC title